Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Pharmacologic Therapies for Sickle Cell Disease
source: Journal of Sickle Cell Disease and Hemoglobinopathies (JSCDH)
year: 2016
authors: Lanetta Bronte, Kenneth I. Ataga, Kenneth Ataga, Lakiea, Bailey, Iris Buchanan, Gregory Kato, Ify Osunkwo, Betty Pace
summary/abstract:Sickle cell disease (SCD) is a multisystem disease, associated with episodes of acute illness and progressive organ damage. Despite its low prevalence in the United States, SCD is one of the most common severe monogenic disorders worldwide, with an estimated 230,000 affected children born every year in sub-Saharan Africa. As a result of its multiple complications, SCD is associated with an overall decreased life expectancy. In addition, the economic burden of SCD is enormous – a consequence of recurrent and chronic SCD-related complications, frequent absences from school and work, and physical impairment limiting the ability to contribute to society.
Although there is an increased understanding of the pathophysiology of SCD, available pharmacologic treatments remain limited. The current approach to the management of SCD includes supportive treatments with folic acid; symptomatic treatment with analgesics, intravenous fluids, oxygen and red blood cell (RBC) transfusion; disease-modifying treatment with hydroxyurea and RBC transfusion; and curative therapy with bone marrow transplantation. Despite the success of bone marrow transplantation as a curative approach in SCD, this modality is limited by its high cost, decreased availability of suitable donors and toxicity.
read moreRelated Content
-
Magnesium for treating sickle cell diseaseBACKGROUND: Sickle cell disease is an a...
-
A new Sickle Cell Disease Drug Holds Much Promise but Most Sufferers Won’t be Able to Afford itThe regulatory approval of a groundbreak...
-
Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical TrialBackground: Sickle cell anemia (SCA), ...
-
Sickle Cell Patient Receives CRISPR Gene TherapyMany human diseases can be traced back t...
-
Investigational Therapy Altemia Achieves Main Endpoints in Pediatric Sickle Cell TrialSancilio Pharmaceuticals says its invest...
-
Bioverativ and Bicycle Therapeutics Enter into Strategic Research Collaboration to Develop Therapies for Hemophilia ...Bioverativ Inc. (NASDAQ: BIVV), a global...
-
La Jolla Pharmaceutical company announces initiation of pivotal clinical study of LJPC-401 in patients with beta tha...La Jolla Pharmaceutical company today an...
Don’t forget to join the oneSCDvoice community!
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.